Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT06657222

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Led by Tubulis GmbH · Updated on 2026-03-03

250

Participants Needed

16

Research Sites

207 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 as a single drug given to patients with solid cancer Researchers will also compare doses of TUB-030 in two specific cancer types, in patients with head and neck cancer and patients with non-small cell lung cancer, to see if TUB-030 works to treat these two solid cancer types and to determine the best dose. Participants will: Receive drug TUB-030 every 3 weeks Visit the clinic once every 3 weeks for checkups and tests Answer patient reported outcome questionnaires about their symptoms

CONDITIONS

Official Title

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 years or older
  • Male or non-pregnant, non-breastfeeding female
  • Adequate organ function
  • Last dose of anti-cancer treatment at least 4 weeks ago (6 weeks for nitrosourea, mitomycin-C) or 5 half-lives, whichever is shorter
  • Any side effects from prior therapy, radiotherapy, or surgery resolved to grade 1 or less
  • Clinically stable brain metastases after radiation therapy if present
  • Final dose of radiotherapy outside the brain at least 28 days before first treatment day; for palliative radiotherapy, at least 14 days prior
  • Measurable disease by RECIST v1.1 within 4 weeks before first treatment day
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Life expectancy greater than 12 weeks
  • Able and willing to give signed informed consent
  • Women of childbearing potential using highly effective contraception and agreeing to continue during and after treatment
  • Men using effective barrier contraception during and after treatment and agreeing to avoid sperm donation
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 16 locations

1

Yale Cancer Center

New Haven, Connecticut, United States, 06510

Actively Recruiting

2

University of Miami

Miami, Florida, United States, 33136

Actively Recruiting

3

Dana Farber Cancer Institute

Boston, Massachusetts, United States, 02215

Actively Recruiting

4

Mayo Clinic

Rochester, Minnesota, United States, 55905

Actively Recruiting

5

Washington University

St Louis, Missouri, United States, 63130

Actively Recruiting

6

Mount Sinai

New York, New York, United States, 11766

Actively Recruiting

7

Cleveland Clinic

Cleveland, Ohio, United States, 44195

Actively Recruiting

8

Ohio State University

Columbus, Ohio, United States, 43210

Actively Recruiting

9

NEXT Oncology Austin

Austin, Texas, United States, 78758

Actively Recruiting

10

NEXT Oncology - Dallas

Irving, Texas, United States, 75039

Actively Recruiting

11

NEXT Oncology - San Antonio

San Antonio, Texas, United States, 78229

Actively Recruiting

12

Fred Hutchinson Cancer Center

Seattle, Washington, United States, 98109

Actively Recruiting

13

Princess Margaret

Toronto, Canada

Actively Recruiting

14

Arensia Exploratory Medicine

Bucharest, Romania

Actively Recruiting

15

Arensia Exploratory Medicine

Cluj-Napoca, Romania

Actively Recruiting

16

Clinica Uni de Navara

Madrid, Spain

Actively Recruiting

Loading map...

Research Team

T

Tubulis Clinical Trial Inquiries

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here